Teva marketing three-tranche euro-denominated M&A bond

July 20, 2016 8:33 AM

13 0

LONDON, July 20 (IFR) - Teva Pharmaceutical has started marketing an expected 4bn multi-tranche euro bond issue to help fund its US$40.5bn acquisition of Actavis Generics, according to a lead bank.

Initial price thoughts on the four-year euro tranche are mid-swaps plus 100bp area, on the eight-year mid-swaps plus 140bp area, and on the 12-year mid-swaps plus 165bp area.

Also read: BRIEF-Newstar sells equipment finance business to Radius Bank for $140 mln

Read more

To category page

Loading...